CRP and atherosclerosis: Longer disease duration may contribute to chronic vascular remodelling, cumulative glucocorticoid or immunosuppressive exposure can suppress or modify FDG signal intensity, and varying levels of systemic inflammation (e.g., CRP elevation) may affect metabolic activity independent of atherosclerosis.